Prevalence of Dissociative Disorders in Children

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nice
ClinicalTrials.gov Identifier:
NCT01512641
First received: December 13, 2011
Last updated: January 31, 2014
Last verified: January 2014
  Purpose

Schizophrenia beginning before 18 years is a clinical entity not well known because of its low incidence and difficulties in the clinical diagnosis.

However, in the investigators clinical practice, due to the specialization of the investigators service, the investigators are led to hospital to receive important feel active of patients meeting the Diagnostic and Statistical Manual of Mental Disorders IV text revision (DSM IV-TR) precose schizophrenia.

The work of us team on the theme of the relationship between Pervasive Developmental Disorders and precose Schizophrenia led us to hypothesize that a number of children in care in the medical and educational institutes, hospitals and day shelters therapeutic part-time symptoms of schizophrenia or a line real early diagnosis of schizophrenia undervalued or not diagnosed.

The main goal is to estimate the prevalence of dissociative disorders in a population of children in care institutions and medical education in child psychiatry in hospitals and others structures.


Condition Intervention
Dissociative Disorders
Schizophrenia
Other: Primary stage
Other: Secondary stage

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Prevalence of Dissociative Disorders in Children in a Population Supported in the Medico-social and Health Structures in Provence Alpes Cote d'Azur

Resource links provided by NLM:


Further study details as provided by Centre Hospitalier Universitaire de Nice:

Primary Outcome Measures:
  • Rate of children diagnosed with dissociative disorders [ Time Frame: between 2 and 4 hours depending children ] [ Designated as safety issue: No ]
    Rate of children diagnosed with dissociative disorders: children positive for the test Kiddie-Schedule for Affective Disorders and Schizophrenia (Kiddie-SADS).


Secondary Outcome Measures:
  • Percentage of children positive for test: Autism Diagnostic Interview-Revise (ADI-R). [ Time Frame: 1 day on average ] [ Designated as safety issue: No ]
  • Scores of three dimensions of schizophrenia in the Positive And Negative Syndrome Scale (PANSS) [ Time Frame: 4 hours ] [ Designated as safety issue: No ]
    3 dimensions: positive symptoms, negative symptoms and general psychopathology, based on these scores the diagnostic subtype of schizophrenia is established.

  • Score at the Test Lillois de Communication (TLC) [ Time Frame: 30 minutes ] [ Designated as safety issue: No ]
  • Score on the Wechsler Intelligence Scale for Children-Fourth Edition (WISC IV)subtests and overall intelligence quotient (IQ). [ Time Frame: 4 hours ] [ Designated as safety issue: No ]
  • Response time to test verbal fluency, scores on the Trail Making Test A (TMT) and TMT B. [ Time Frame: 30 minutes ] [ Designated as safety issue: No ]

Enrollment: 301
Study Start Date: December 2011
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Children with Dissociative Disorders
Children will take first the primary stage. If one child is positive, he will pass the secondary stage.
Other: Primary stage
Kiddie-Schedule for Affective Disorders and Schizophrenia
Other: Secondary stage
children who are positive to the kiddie-SADS (primary stage), will take the tests: PANSS, Scale for the Assessment of Negative Symptoms (SANS), ADI-R, scale TLC and WISC IV

  Eligibility

Ages Eligible for Study:   7 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 7 to 18 years
  • Supported in the partner institutions of the study
  • IQ>35 on the certificate of orientation of the Maison Départementale des Personnes Handicapées (MDPH)
  • Obtaining the agreement of parents and children

Exclusion Criteria:

  • QI<35 on the certificate file Guidance MDPH
  • Children not speaking french
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01512641

Locations
France
Psychiatrie infanto-juvénile - Centre Hospitalier d'Antibes
Antibes, France, 06600
Psychiatrie infanto-juvénile-Pôle femme-mère -enfant
Fréjus, France, 83608
Service de psychiatrie de l'enfant et de l'adolescent
Marseille, France, 13009
Service de psychiatrie de l'enfant et de l'adolescent
Nice, France, 06000
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nice
Investigators
Study Director: Florence ASKENAZY, PU-PH University hospital of Nice
Principal Investigator: Emmanuelle DOR, PH University hospital of Nice
Principal Investigator: François POINSO, PU-PH AP-HM
Principal Investigator: Michèle BATTISTA, PH Frejus's hospital
Principal Investigator: Michel BOUBLIL, PH Antibes's hospital
  More Information

No publications provided

Responsible Party: Centre Hospitalier Universitaire de Nice
ClinicalTrials.gov Identifier: NCT01512641     History of Changes
Other Study ID Numbers: 11-API-01
Study First Received: December 13, 2011
Last Updated: January 31, 2014
Health Authority: France: Committee for the Protection of Personnes
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Centre Hospitalier Universitaire de Nice:
children dissociative disorders schizophrenia

Additional relevant MeSH terms:
Schizophrenia
Disease
Dissociative Disorders
Conversion Disorder
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Pathologic Processes
Somatoform Disorders

ClinicalTrials.gov processed this record on September 30, 2014